~~<i id='3612B108E5'><strike id='3612B108E5'><tt id='3612B108E5'><pre id='3612B108E5'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：Wikipedia 2025-10-04 11:32:46 Page View：773

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 'Essentially witchcraft:' A former naturopath takes on the field
Next article： Continuity nursing helped my family in our darkest PICU moments

explore

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

NIH tests clinical research in primary care with $30 million program

TheNIH'snewprimarycareresearchnetworkaimstoimproverepresentationinclinicalscience.AdobeFormanyAmeric

How one medical school became remarkably diverse

ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

Study: Why relieving medical debt did not improve financial outcomes

AdobePhilanthropistsandfoundationsliketheoneIworkfortakealotofcalculatedrisks.Weinvestinresearch,adv